CSI Market
Sign In | Register

Anixa Biosciences Inc (ANIX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ANIX Annual Cash Flow →
This cash flow overview for Anixa Biosciences Inc spans from Jul 31 2025 to Jul 31 2026, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jul 31 2026)
9 Months 		(Apr 30 2026) (Jan 31 2026) (Oct 31 2025) (Jul 31 2025)
Operating Activities
Income-7.75
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation2.13
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Stock Granted During Period Value Sharebased Compensation-
Equity Based Payment To Nonemployees Stock Grants-
Stock Issued During Period Value Acquisitions-
Warrants Issued For Fees In Connection With Issuance Of Convertible Debentures-
Proceeds From Patent Monetization And Patent Assertion-
Gain Loss On Derivative Instruments Net Pretax-
Equity Based Payment To Non Employees Stock Options-
Equity Based Payment To Non Employees Stock Grants-
Common Stock Issued To Pay Interest On Convertible Debentures-
Amortized Interest On Patent Acquisition Obligations To Interest Expense-
Stock Option Compensation To Consultants-
Derivative Gain Loss On Derivative Net-
Noncash Or Part Noncash Acquisition Intangible Assets Acquired-
Stock Options And Warrants Issued To Consultants-
Stock Award Compensation To Employee And Directors Pursuant To Stock Incentive Plan-
Issuance Of Stock For Services Or Claims-
Restricted Stock Award Compensation To Employee Pursuant To Stock Incentive Plan-
Operating Lease Rightofuse Asset Amortization-
Increase Decrease In Operating Lease Liability-0.02
Operating Lease Right Of Use Asset Amortization Expense0.02
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Accounts Payable0.12
Increase (Decrease) in Accrued Liabilities-0.34
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.33
Other Working Capital1.31
Other Noncash Income (Expense)0.00
Other net-0.06
Payments for (Proceeds from) Other Operating Activities-1.86
Discontinued operations0.00
Net Cash flow from Operating Activities-6.12
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds1.41
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds Received On Sale Of Common Stock By Zqx Advisors Llc-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities1.41
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock4.66
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.21
Proceeds Received On Sale Of Common Stock From Related Party-
Payments For Repurchase Of Common Stock And Cancellation Of Warrant-
Redemption Of Convertible Preferred Stock-
Payments Made On Secured Debenture-
Proceeds From Issuance Of Rights Offering-
Payment To Acquire Royalty Interest In Patent Rights-
Proceeds From Settlement Of Shareholder Derivative Complaint-
Payments Of Market Offering-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations1.24
Proceeds From Repayment Of Stock Options Exercised-
Disbursements For Purchases Of Treasury Stock-
Net Proceeds Expenses From Market Offering-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities4.87
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-6.12
Total Cash Flow0.15
4 historic quarters locked

Sign in to unlock the full Anixa Biosciences Inc cash flow history.

Sign In Create Free Account

About Anixa Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260731)
  • Filed with the SEC: September 9, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-041963

Figures are derived from filed reports and may be restated. Historical data is subject to revision.